Bio/Pharma Business

Paradigm Shift

January 02, 2023

Cell and gene therapies is unequivocally viewed as the biggest opportunity in the bio/pharma space.

GSK and Wave Life Sciences to Collaborate on Oligonucleotide Therapeutics

December 19, 2022

GSK and Wave Life Sciences have entered into a collaboration to drive drug discovery and development for novel genetic targets.

AbCellera and Rallybio Partner on Novel Antibody-Based Therapeutics

December 19, 2022

AbCellera and Rallybio are teaming up to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases.

Vertex and Entrada Therapeutics Enter Endosomal Escape Vehicle Collaboration

December 14, 2022

Under the collaboration between Vertex and Entrada, the companies will work on discovering and developing intracellular endosomal escape vehicle therapeutics for myotonic dystrophy type 1.

Amgen Inks $27.8 Billion Blockbuster to Acquire Horizon Therapeutics

December 13, 2022

Amgen’s $27.8 billion acquisition of Horizon Therapeutics, an Irish biotechnology company, is one of the largest of 2022.

Takeda to Purchase Autoimmune Treatment for $6 Billion

December 13, 2022

Takeda will purchase the rights to Nimbus Pharmaceuticals candidate, NDI-034858, which is currently being evaluated for treating multiple autoimmune diseases.

Virtual Staining Start-Up Launches with More Than 18.8 Million in Funding

December 12, 2022

PictorLabs, a digital pathology company developing an AI-powered virtual staining platform, formally announced its launch at the start of December.

Shining a Light on Junior Pharmaceuticals

December 03, 2022

Overall industry growth conceals growing numbers of smaller, faster-paced, adaptable corporate structures.

mRNA Hauptbahnhof

December 02, 2022

mRNA may not be a train we necessarily all need to get onboard immediately, but we should know where the central train station is located, and what it connects us to.

AstraZeneca Acquires Neogene Therapeutics for $320 Million

November 30, 2022

AstraZeneca inked a deal worth up to $320 million to purchase Neogene Therapeutics, a biotech start-up focused on T-cell receptor therapies.